Praxis Precision Medicines Inc

+0.98 (+5.14%)
Regulatory, Other Pre-Announcement

Praxis Precision Medicines Reports Qtrly Loss Per Share $0.87

Published: 03/17/2021 11:49 GMT
Praxis Precision Medicines Inc (PRAX) - Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results.
Cash Balance of $296.6 Million As of December 31, 2020 Supports Cash Runway Into 4q22.
Prax-114 Phase 2/3 Clinical Trial for Treatment of Mdd to Initiate in March 2021 Following Ind Clearance.
Prax-944 Phase 2a High Dose Cohort Topline Data Expected in Mid-year 2021.
Qtrly Loss per Share $0.87.
Q4 Earnings per Share View $-0.38 -- Refinitiv Ibes Data (analyst estimates).